This video is sponsored by the Duke Clinical Medical Series.
Topics include:
* The Intersection of Acute Coronary Syndromes and Atherothrombosis in Contemporary
Clinical Practice
* Goals for CRUSADE: Improve Adherence to ACC/AHA Guidelines for Unstable
Angina/Non-ST-Elevation MI
* CRUSADE Patient Features
* CRUSADE Patient Characteristics
* CRUSADE In-Hospital Outcomes
* CRUSADE Acute Care Patterns
* CRUSADE Acute Medication Use (Within 1st 24 hrs in pts w/out contraindications)
* CRUSADE Contraindications to Acute (< 24 hrs) Medication Use by Age
* CRUSADE Invasive Cardiac Procedures (Excluding 25% of patients w/contraindications to
cath)
* Trends in Type of Revascularization Strategy for 3-Vessel CAD in CRUSADE
The moderator, Kristin Newby, MD, has indicated that she receives research/grant support
from Bristol-Myers Squibb, Sanofi, Millennium Pharmaceuticals, Inc., Schering-Plough
Research Institute, Novartis and Roche Diagnostics Corporation. Dr. Newby is also a member
of an advisory board for Eli Lilly and a consultant for Proctor and Gamble; she has spoken
at scientific symposia for Aventis, Bristol-Myers Squibb, Sanofi and Millennium
Pharmaceuticals, Inc.
The guest faculty, Matthew Roe, MD, has indicated that he serves as a consultant for - and
receives research/grant support from - Schering Plough, BMS-Sanofi, Lilly, Daiichi-Sankyo,
KAI Pharmaceuticals, and DeCode Genetics. He serves on the speakers bureau of Schering
Plough and BMS-Sanofi. He has performed Clinical Events Committee event review for
Genentech, Novartis, and Conor.
n/a
|
|